Literature DB >> 27900455

Bilateral atypical femur fractures without bisphosphonate exposure.

Lauren K Szolomayer1, Izuchukwu K Ibe2, Dieter M Lindskog2.   

Abstract

Atypical femur fractures have common radiographic features that set them apart from more typical higher-energy subtrochanteric femur fractures. They are noncomminuted, transverse fractures with medial spiking of the femoral cortex and increased lateral cortical thickness. These fractures have been associated in the literature with the use of bisphosphonate medications. This case describes bilateral atypical femur fractures in a patient with a medical history devoid of bisphosphonate use. We present his history, co-morbidities, and subsequent treatment. From this case, we call attention to bisphosphonate use as not the only cause of subtrochanteric femur fractures with atypical features and highlight that some patients may sustain these injuries even bilaterally without use of the medications. In addition, it is important to identify this fracture type and obtain imaging of the contralateral femur to facilitate prophylactic treatment if needed.

Entities:  

Keywords:  Antiresorptive therapy; Atypical femur fracture; Bisphosphonates; Fracture; Fracture fixation; Intramedullary; Stress

Mesh:

Substances:

Year:  2016        PMID: 27900455     DOI: 10.1007/s00256-016-2526-0

Source DB:  PubMed          Journal:  Skeletal Radiol        ISSN: 0364-2348            Impact factor:   2.199


  34 in total

1.  Bisphosphonates for osteoporosis--where do we go from here?

Authors:  Marcea Whitaker; Jia Guo; Theresa Kehoe; George Benson
Journal:  N Engl J Med       Date:  2012-05-09       Impact factor: 91.245

Review 2.  Bisphosphonates and risk of subtrochanteric, femoral shaft, and atypical femur fracture: a systematic review and meta-analysis.

Authors:  Lydia Gedmintas; Daniel H Solomon; Seoyoung C Kim
Journal:  J Bone Miner Res       Date:  2013-08       Impact factor: 6.741

3.  Bilateral atypical femoral fractures: how much symmetry is there on imaging?

Authors:  Linda Probyn; Angela M Cheung; Catherine Lang; Leon Lenchik; Jonathan D Adachi; Aliya Khan; Robert G Josse; George Tomlinson; Robert Bleakney
Journal:  Skeletal Radiol       Date:  2015-07-14       Impact factor: 2.199

Review 4.  Atypical fractures of the femur and bisphosphonate therapy: A systematic review of case/case series studies.

Authors:  Andrea Giusti; Neveen A T Hamdy; Socrates E Papapoulos
Journal:  Bone       Date:  2010-05-20       Impact factor: 4.398

5.  Losartan increases bone mass and accelerates chondrocyte hypertrophy in developing skeleton.

Authors:  Shan Chen; Monica Grover; Tarek Sibai; Jennifer Black; Nahid Rianon; Abbhirami Rajagopal; Elda Munivez; Terry Bertin; Brian Dawson; Yuqing Chen; Ming-Ming Jiang; Brendan Lee; Tao Yang; Yangjin Bae
Journal:  Mol Genet Metab       Date:  2015-02-27       Impact factor: 4.797

Review 6.  Use of bisphosphonates in older adults: how long is long enough?

Authors:  Rebecca L Dunn; Matthew L Bird; Susan E Conway; Mark A Stratton
Journal:  Consult Pharm       Date:  2013-01

7.  Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study.

Authors:  Bo Abrahamsen; Pia Eiken; Richard Eastell
Journal:  J Bone Miner Res       Date:  2009-06       Impact factor: 6.741

Review 8.  Atypical femur fractures: a review.

Authors:  Wesley H Bronson; I David Kaye; Kenneth A Egol
Journal:  Curr Osteoporos Rep       Date:  2014-12       Impact factor: 5.096

9.  Bilateral fractures of the femur diaphysis in a patient with rheumatoid arthritis on long-term treatment with alendronate: clues to the mechanism of increased bone fragility.

Authors:  Matthijs P Somford; Frits W Draijer; Bregje J W Thomassen; Pascale M Chavassieux; Georges Boivin; Socrates E Papapoulos
Journal:  J Bone Miner Res       Date:  2009-10       Impact factor: 6.741

Review 10.  Subtrochanteric fractures after long-term treatment with bisphosphonates: a European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, and International Osteoporosis Foundation Working Group Report.

Authors:  R Rizzoli; K Akesson; M Bouxsein; J A Kanis; N Napoli; S Papapoulos; J-Y Reginster; C Cooper
Journal:  Osteoporos Int       Date:  2010-11-18       Impact factor: 4.507

View more
  4 in total

1.  Atypical femur fracture in a woman with osteogenesis imperfecta and multiple myeloma.

Authors:  Yuxi Chen; Michael Sebag; Thomas I Powell; Suzanne N Morin
Journal:  J Musculoskelet Neuronal Interact       Date:  2018-09-01       Impact factor: 2.041

2.  Atypical Femoral Fracture in a Patient without Bisphosphonate or Denosumab Exposure-A Case Report.

Authors:  George F Georgiadis; Dimitrios G Begkas; Konstantinos A Maniatis; Alexandros E Vasilakis; Stamatios Theodoros D Chatzopoulos; Alexia P Balanika
Journal:  J Orthop Case Rep       Date:  2021-10

Review 3.  Genetic Risk Factors for Atypical Femoral Fractures (AFFs): A Systematic Review.

Authors:  Hanh H Nguyen; Denise M van de Laarschot; Annemieke JMH Verkerk; Frances Milat; M Carola Zillikens; Peter R Ebeling
Journal:  JBMR Plus       Date:  2018-01-03

4.  Medical Management of Patients After Atypical Femur Fractures: a Systematic Review and Recommendations From the European Calcified Tissue Society.

Authors:  Denise M van de Laarschot; Malachi J McKenna; Bo Abrahamsen; Bente Langdahl; Martine Cohen-Solal; Núria Guañabens; Richard Eastell; Stuart H Ralston; M Carola Zillikens
Journal:  J Clin Endocrinol Metab       Date:  2020-05-01       Impact factor: 5.958

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.